Details of the Drug

General Information of Drug (ID: DMF8Y74)

• Drug Name: Hydroxyzine
• Synonyms: Atara; Atarax; Ataraxoid; Atarazoid; Atarox; Atazina; Aterax; Deinait; Durrax; Hidroxizina; Hychotine; Hydroksyzyny; Hydroxine; Hydroxizine; Hydroxizinum; Hydroxycine; Hydroxyzin; Hydroxyzinum; Hydroxyzyne; Idrossizina; Neurozina; Nevrolaks; Orgatrax; Pamazone; Parenteral; Paxistil; Placidol; Plaxidol; Tranquizine; Traquizine; Vistaril; Atarax base; Hydroksyzyny [Polish]; Hydroxyzine Hcl; Hydroxyzine base; Hydroxyzine hydrochloride; Idrossizina [DCIT]; NP 212; UCB 4492; UCB 492; Atarax (TN); Hidroxizina [INN-Spanish]; Hy-Pam 25; Hydroxyzine (INN); Hydroxyzine [INN:BAN]; Hydroxyzinum [INN-Latin]; Marex (TN); Neo-Calma; Tran-Q; U.CB 4492; Vesparaz-Wirkstoff; Vistaril (TN); U.C.B 4492; N-(4-Chlorobenzhydryl)-N'-(hydroxyethoxyethyl)piperazine; N-(4-Chlorobenzhydryl)-N'-(hydroxyethyloxyethyl)piperazine; Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-(9CI); 1-(p-Chloro-.alpha.-phenylbenzyl)-4-[2-[(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-hydroxyethoxyethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]diethylenediamine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chlorodiphenylmethyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorodiphenylmethyl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 2-(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-(4-(p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]ethanol; 2-[2-[4-(p-Chloro-.alpha.-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1]
Anxiety disorder	6B00-6B0Z	Approved	[2]
Urticaria	EB00-EB05	Approved	[1]
Pruritus	EC90	Investigative	[1]

• Therapeutic Class: Hypnotics and Sedatives
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 374.9
  Logarithm of the Partition Coefficient (xlogp); 3.7
  Rotatable Bond Count (rotbonds); 8
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 2600 mcg/L [3]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3-5 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Bioavailability: The bioavailability of drug is 76% [3]
  Clearance: The clearance of drug is 31.1 +/- 11.1 mL/min/kg [5]
  Elimination: Approximately 70% of hydroxyzine's active metabolite, cetirizine, is excreted unchanged in the urine [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 14 - 25 hours [7]
  Metabolism: The drug is metabolized via the liver [7]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.2418 micromolar/kg/day [8]
  Vd: The volume of distribution (Vd) of drug is 16.0 +/- 3.0 L/kg [7]
  Water Solubility: The ability of drug to dissolve in water is measured as 700 mg/mL [4]
• Chemical Identifiers:
  Formula: C21H27ClN2O2
  IUPAC Name: 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
  Canonical SMILES: C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
  InChI: InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2
  InChIKey: ZQDWXGKKHFNSQK-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3658
  ChEBI ID: CHEBI:5818
  CAS Number: 68-88-2
  DrugBank ID: DB00557
  TTD ID: D0O6SX
  INTEDE ID: DR0840
  ACDINA ID: D00318
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 3A5 (CYP3A5) Main DME	DEIBDNY	CP3A5_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[11]
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[12]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Gene/Protein Processing	[12]
Interleukin-24 (IL24)	OT4VUWH1	IL24_HUMAN	Gene/Protein Processing	[12]
Phosphatidylcholine translocator ABCB4 (ABCB4)	OTE6PY83	MDR3_HUMAN	Gene/Protein Processing	[13]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[9]
PTB-containing, cubilin and LRP1-interacting protein (PID1)	OT5YJ7FI	PCLI1_HUMAN	Gene/Protein Processing	[12]
Transmembrane protease serine 2 (TMPRSS2)	OTN44YQ5	TMPS2_HUMAN	Gene/Protein Processing	[11]

Molecular Expression Atlas of This Drug

• The Studied Disease: Allergic rhinitis
• ICD Disease Classification: CA08.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.57E-01	9.43E-03	1.29E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Hydroxyzine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[14]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Midostaurin.	Acute myeloid leukaemia [2A60]	[15]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Idarubicin.	Acute myeloid leukaemia [2A60]	[15]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[15]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Arn-509.	Acute myeloid leukaemia [2A60]	[16]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[17]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Hydroxyzine and Oliceridine.	Acute pain [MG31]	[18]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[19]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[20]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[20]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[19]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Memantine.	Alzheimer disease [8A20]	[19]
Galantamine	DMEO794	Moderate	Antagonize the effect of Hydroxyzine when combined with Galantamine.	Alzheimer disease [8A20]	[21]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Hydroxyzine when combined with Rivastigmine.	Alzheimer disease [8A20]	[21]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Hydroxyzine when combined with Donepezil.	Alzheimer disease [8A20]	[21]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Hydroxyzine and Metronidazole.	Amoebiasis [1A36]	[22]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Ivabradine.	Angina pectoris [BA40]	[16]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Dronedarone.	Angina pectoris [BA40]	[15]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Cilostazol.	Arterial occlusive disease [BD40]	[15]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Posaconazole.	Aspergillosis [1F20]	[15]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Levalbuterol.	Asthma [CA23]	[23]
Terbutaline	DMD4381	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Terbutaline.	Asthma [CA23]	[24]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Pirbuterol.	Asthma [CA23]	[24]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Salbutamol.	Asthma [CA23]	[23]
Formoterol	DMSOURV	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Formoterol.	Asthma [CA23]	[24]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[16]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[19]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[15]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Hydroxyzine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[15]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Linezolid	DMGFPU2	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Linezolid.	Bacterial infection [1A00-1C4Z]	[15]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[15]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Cariprazine.	Bipolar disorder [6A60]	[19]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Hydroxyzine and Loperamide.	Bowel habit change [ME05]	[26]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Eribulin.	Breast cancer [2C60-2C6Y]	[15]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Lapatinib.	Breast cancer [2C60-2C6Y]	[15]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[15]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Bosutinib.	Breast cancer [2C60-2C6Y]	[16]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Hydroxyzine when combined with Acetylcholine.	Cataract [9B10]	[27]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[28]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[29]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[29]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[29]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Hydroxyzine and Dihydrocodeine.	Chronic pain [MG30]	[30]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Isoproterenol.	Conduction disorder [BC63]	[23]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Olopatadine.	Conjunctiva disorder [9A60]	[31]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Halothane.	Corneal disease [9A76-9A78]	[15]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Propofol.	Corneal disease [9A76-9A78]	[32]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Sevoflurane.	Corneal disease [9A76-9A78]	[15]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Hydroxyzine and Alfentanil.	Corneal disease [9A76-9A78]	[18]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Hydroxyzine and Remifentanil.	Corneal disease [9A76-9A78]	[18]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Probucol.	Coronary atherosclerosis [BA80]	[15]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Clofazimine.	Crohn disease [DD70]	[33]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Mifepristone.	Cushing syndrome [5A70]	[15]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Pasireotide.	Cushing syndrome [5A70]	[15]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Osilodrostat.	Cushing syndrome [5A70]	[16]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Ethanol.	Cystitis [GC00]	[31]
Trimipramine	DM1SC8M	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Trimipramine.	Depression [6A70-6A7Z]	[19]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[19]
Isocarboxazid	DMAF1NB	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Isocarboxazid.	Depression [6A70-6A7Z]	[15]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Escitalopram.	Depression [6A70-6A7Z]	[15]
Tranylcypromine	DMGB5RE	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Tranylcypromine.	Depression [6A70-6A7Z]	[15]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and OPC-34712.	Depression [6A70-6A7Z]	[19]
Phenelzine	DMHIDUE	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Phenelzine.	Depression [6A70-6A7Z]	[15]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Clomipramine.	Depression [6A70-6A7Z]	[19]
Trazodone	DMK1GBJ	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Trazodone.	Depression [6A70-6A7Z]	[34]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Doxepin.	Depression [6A70-6A7Z]	[19]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Maprotiline.	Depression [6A70-6A7Z]	[19]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Esketamine.	Depression [6A70-6A7Z]	[22]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Mepenzolate.	Digestive system disease [DE2Z]	[19]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Oxybutynine.	Discovery agent [N.A.]	[19]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[15]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Meclizine.	Dizziness and giddiness [MB48]	[19]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Ingrezza.	Dystonic disorder [8A02]	[35]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Hydroxyzine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[36]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[19]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Solifenacin.	Functional bladder disorder [GC50]	[19]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Tolterodine.	Functional bladder disorder [GC50]	[19]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Pentamidine.	Fungal infection [1F29-1F2F]	[15]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Ketoconazole.	Fungal infection [1F29-1F2F]	[15]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Propantheline.	Gastric ulcer [DA60]	[19]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[15]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[15]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Hydroxyzine when combined with Isoflurophate.	Glaucoma [9C61]	[27]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Hydroxyzine when combined with Pilocarpine.	Glaucoma [9C61]	[27]
Procarbazine	DMIK367	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Procarbazine.	Hodgkin lymphoma [2B30]	[15]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[19]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Amantadine.	Influenza [1E30-1E32]	[40]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Propiomazine.	Insomnia [7A00-7A0Z]	[19]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and ITI-007.	Insomnia [7A00-7A0Z]	[19]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[16]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[15]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Clidinium.	Irritable bowel syndrome [DD91]	[19]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Dicyclomine.	Irritable bowel syndrome [DD91]	[19]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Hydroxyzine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[21]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Crizotinib.	Lung cancer [2C25]	[41]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Ceritinib.	Lung cancer [2C25]	[15]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Osimertinib.	Lung cancer [2C25]	[42]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Selpercatinib.	Lung cancer [2C25]	[16]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Lumefantrine.	Malaria [1F40-1F45]	[22]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Halofantrine.	Malaria [1F40-1F45]	[43]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Chloroquine.	Malaria [1F40-1F45]	[44]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Hydroxychloroquine.	Malaria [1F40-1F45]	[44]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Primaquine.	Malaria [1F40-1F45]	[15]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[16]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[45]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Vemurafenib.	Melanoma [2C30]	[15]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and LGX818.	Melanoma [2C30]	[46]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[47]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Lasmiditan.	Migraine [8A80]	[48]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Flibanserin.	Mood disorder [6A60-6E23]	[49]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Panobinostat.	Multiple myeloma [2A83]	[50]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Thalidomide.	Multiple myeloma [2A83]	[51]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Siponimod.	Multiple sclerosis [8A40]	[22]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Fingolimod.	Multiple sclerosis [8A40]	[15]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Ozanimod.	Multiple sclerosis [8A40]	[52]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Romidepsin.	Mycosis fungoides [2B01]	[15]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[15]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[53]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Phenindamine.	Nasopharyngitis [CA00]	[19]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Dimenhydrinate.	Nausea/vomiting [MD90]	[19]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Promethazine.	Nausea/vomiting [MD90]	[19]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Cyclizine.	Nausea/vomiting [MD90]	[19]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Granisetron.	Nausea/vomiting [MD90]	[15]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Dolasetron.	Nausea/vomiting [MD90]	[15]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Ondansetron.	Nausea/vomiting [MD90]	[15]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Entrectinib.	Non-small cell lung cancer [2C25]	[22]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[16]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Lofexidine.	Opioid use disorder [6C43]	[15]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Hydroxyzine and Pentazocine.	Pain [MG30-MG3Z]	[18]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Hydroxyzine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[54]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Hydroxyzine and Butorphanol.	Pain [MG30-MG3Z]	[18]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Hydroxyzine and Oxymorphone.	Pain [MG30-MG3Z]	[18]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Hydroxyzine and Levorphanol.	Pain [MG30-MG3Z]	[18]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Hydroxyzine and Dezocine.	Pain [MG30-MG3Z]	[18]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Flavoxate.	Pain [MG30-MG3Z]	[19]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Hydroxyzine and Nalbuphine.	Pain [MG30-MG3Z]	[18]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Hydroxyzine and Buprenorphine.	Pain [MG30-MG3Z]	[55]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Hydroxyzine and Hydrocodone.	Pain [MG30-MG3Z]	[18]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Triclabendazole.	Parasitic worm infestation [1F90]	[15]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Biperiden.	Parkinsonism [8A00]	[19]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Pimavanserin.	Parkinsonism [8A00]	[56]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Orphenadrine.	Parkinsonism [8A00]	[19]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Apomorphine.	Parkinsonism [8A00]	[15]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Methylscopolamine.	Peptic ulcer [DA61]	[19]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Famotidine.	Peptic ulcer [DA61]	[22]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[57]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Lefamulin.	Pneumonia [CA40]	[58]
Ritodrine	DM4V6RL	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Ritodrine.	Preterm labour/delivery [JB00]	[24]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Degarelix.	Prostate cancer [2C82]	[16]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and ABIRATERONE.	Prostate cancer [2C82]	[16]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Nilutamide.	Prostate cancer [2C82]	[16]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Enzalutamide.	Prostate cancer [2C82]	[16]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Relugolix.	Prostate cancer [2C82]	[16]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Bicalutamide.	Prostate cancer [2C82]	[16]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[19]
Fluphenazine	DMIT8LX	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[19]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[59]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Quetiapine.	Schizophrenia [6A20]	[15]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Mesoridazine.	Schizophrenia [6A20]	[15]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Thioridazine.	Schizophrenia [6A20]	[15]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Aripiprazole.	Schizophrenia [6A20]	[19]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Iloperidone.	Schizophrenia [6A20]	[15]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Paliperidone.	Schizophrenia [6A20]	[19]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Perphenazine.	Schizophrenia [6A20]	[19]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Molindone.	Schizophrenia [6A20]	[19]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Thiothixene.	Schizophrenia [6A20]	[19]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Trifluoperazine.	Schizophrenia [6A20]	[19]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Risperidone.	Schizophrenia [6A20]	[19]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Amisulpride.	Schizophrenia [6A20]	[60]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Asenapine.	Schizophrenia [6A20]	[15]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Pimozide.	Schizophrenia [6A20]	[16]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Hydroxyzine and Fentanyl.	Sensation disturbance [MB40]	[18]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Hydroxyzine and Sufentanil.	Sensation disturbance [MB40]	[18]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[15]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[15]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[15]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[15]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[15]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[15]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Lenvatinib.	Thyroid cancer [2D10]	[15]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Cabozantinib.	Thyroid cancer [2D10]	[16]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Papaverine.	Tonus and reflex abnormality [MB47]	[61]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Hydroxyzine and Tizanidine.	Tonus and reflex abnormality [MB47]	[62]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Tacrolimus.	Transplant rejection [NE84]	[15]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Atropine.	Unspecific substance harmful effect [NE6Z]	[19]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[15]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[19]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[19]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[19]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[20]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[19]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[19]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Hydroxyzine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[19]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[15]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[15]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Hydroxyzine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[15]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Hydroxyzine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[15]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Glyceryl monostearate	E00310	24699	Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydrazine yellow	E00409	164825	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Ferrous oxide	E00241	14945	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Water	E00035	962	Solvent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Hydroxyzine 100 mg capsule	100 mg	Oral Capsule	Oral
Hydroxyzine 50 mg capsule	50 mg	Oral Capsule	Oral
Hydroxyzine 25 mg capsule	25 mg	Oral Capsule	Oral
Hydroxyzine Hydrochloride 10mg tablet	10mg	Tablet	Oral
Hydroxyzine Hydrochloride 50mg tablet	50mg	Tablet	Oral
Hydroxyzine Hydrochloride 25mg tablet	25mg	Tablet	Oral
Hydroxyzine 25 mg tablet	25 mg	Oral Tablet	Oral
Hydroxyzine 50 mg tablet	50 mg	Oral Tablet	Oral
Hydroxyzine 10 mg tablet	10 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Hydroxyzine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7199).
• [3] Rayner-Hartley E, Sedlak T: Ranolazine: A Contemporary Review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196. doi: 10.1161/JAHA.116.003196.
• [4] BDDCS applied to over 900 drugs
• [5] Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97.
• [6] Simons KJ, Watson WT, Chen XY, Simons FE: Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. Clin Pharmacol Ther. 1989 Jan;45(1):9-14. doi: 10.1038/clpt.1989.2.
• [7] Understanding the pharmacokinetics of anxiolytic drugs. Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):423-40. doi: 10.1517/17425255.2013.759209. Epub 2013 Jan 21.
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient ... J Pharmacol Sci. 2008 Dec;108(4):462-71.
• [10] Product characteristics of HYDROXYZINE (Hydroxyzine Hydrochloride Capsules).
• [11] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [12] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [13] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [14] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [15] Canadian Pharmacists Association.
• [16] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [17] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [18] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [19] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [20] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [21] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [22] Cerner Multum, Inc. "Australian Product Information.".
• [23] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [24] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [25] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [26] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [27] Multum Information Services, Inc. Expert Review Panel.
• [28] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [29] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [30] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [31] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [32] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [33] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [34] Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
• [35] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [36] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [37] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [38] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [39] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [40] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [41] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [42] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [43] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [44] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [45] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [46] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [47] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [48] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [49] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [50] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [51] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [52] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [53] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [54] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
• [55] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
• [56] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [57] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [58] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [59] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [60] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [61] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [62] Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.